Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.69 |
| ▸ | IGF1R | P08069 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979453 | 1.00 | GAA (0.71) | GAAMEN1KMT2AKDM4EOPRM1 | |
| SCHEMBL1205842 | 1.00 | GAA (0.71) | GAAMEN1KMT2AKDM4EOPRM1 | |
| SCHEMBL12573567 | 0.98 | GAA (0.69) | GAAMEN1KMT2AKDM4EOPRM1 | |
| SCHEMBL8223804 | 0.98 | GAA (0.69) | GAAMEN1KMT2AKDM4EOPRM1 | |
| Hydrochloric Acid SCHEMBL3089754 | 0.98 | GAA (0.69) | GAAMEN1KMT2AKDM4EOPRM1 | |
| SCHEMBL1460306 | 0.98 | GAA (0.69) | GAAMEN1KMT2AKDM4EOPRM1 | |
| SCHEMBL2796836 | 0.92 | GAA (0.82) | GAAMEN1KMT2AKDM4EOPRM1 | |
| SCHEMBL10746494 | 0.92 | GAA (0.82) | GAAMEN1KMT2AKDM4EOPRM1 | |
| SCHEMBL3976521 | 0.86 | GAA (0.74) | GAAMEN1KMT2AKDM4EOPRM1 | |
| SCHEMBL679175 | 0.85 | KDM4E (0.55) | GAAMEN1KMT2AKDM4EOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2019-02-14 | — | — | US | disclosed |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-11-20 | — | — | US | disclosed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | disclosed |
| EP-3034500-A1 | Amido thiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-7799952-B2 | Stereoselective method for the production of (R)-Dimepranol | RATIOPHARM GMBH (DE) | 2010-09-21 | — | — | US | disclosed |
| CN-100522970-C | Stereoselective method for the production of clopidogrel | RATIOPHARM GMBH (DE) | 2009-08-05 | — | — | CN | disclosed |
| US-20090149677-A1 | Stereoselective Method for the Production of (R)-Dimepranol | RATIOPHARM GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7507827-B2 | Stereoselective method for the production of Clopidogrel | RATIOPHARM GMBH (DE) | 2009-03-24 | — | — | US | disclosed |
| EP-1737868-B1 | STEREOSELECTIVE METHOD FOR THE PRODUCTION OF CLOPIDOGREL | RATIOPHARM GMBH (DE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070219166-A1 | Stereoselective Method for the Production of Clopidogrel | RATIOPHARM GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| CN-1972950-A | Stereoselective process for preparing clopidogrel | RATIOPHARM GMBH (DE) | 2007-05-30 | — | — | CN | disclosed |
| EP-1589019-A1 | Stereoselective process for the preparation of Clopidogrel | Ratiopharm GmbH (DE) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | GAA 507/4885MEN1 4380/4885KMT2A 3963/4885 |
| US-20090149677-A1 | Stereoselective Method for the Production of (R)-Dimepranol | ADH5, ADH1A, ADH1C | GAA 2362/4885MEN1 1230/4885KMT2A 3032/4885 |
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | GAA 507/4885MEN1 4380/4885KMT2A 3963/4885 |
| US-20070219166-A1 | Stereoselective Method for the Production of Clopidogrel | CYP2C19, ADH1C, TBXA2R | GAA 1963/4885MEN1 3470/4885KMT2A 2966/4885 |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | NOX1, NOX5, CYBB | GAA 507/4885MEN1 4380/4885KMT2A 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.